title: [The acquisition of medication to treat Alzheimer's disease in Brazil: an analysis of federal purchases, 2008-2013].
abstract: The demographic transition in Brazil has led to substantial aging of the population and an increased prevalence of age-related diseases such as dementia and Alzheimer's Disease (AD). The Brazilian Ministry of Health finances AD medication and, since 2002, a Clinical Protocol and Therapeutic Guidelines (PCDT) for this condition have been made available. This study investigated the acquisition of medication for AD in the Integrated System of Administration of General Services (SIASG) database. A profile of purchases, expenditures and prices from 2008 to 2013 was prepared. All medication and forms of treatment of AD were investigated, including those not contained in the PCDT protocol. Unit prices were deflated to December 2013 by the IPCA (Brazilian Pricing Index). More than 47 million units of medication for AD were acquired and expenditures attained 90.1 million Brazilian reals. The purchase of the various administration routes of rivastigmine were in the forefront. Medication not listed in the protocol represented 3% of expenditures and purchases resulting from health litigation were negligible. Over the period, a reduction of corrected weighted average prices of PCDT and non-PCDT medication was observed.
authors.affiliation: Departamento de Política, Planejamento e Administração em Saúde, Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brasil, roberta_fdacosta@yahoo.com.br.
authors.forename: Roberta Dorneles Ferreira
authors.initials: RD
authors.lastname: da Costa
authors.affiliation: Núcleo de Assistência Farmacêutica, Escola Nacional de Saúde Pública Sergio Arouca, Fiocruz.
authors.forename: Claudia Garcia Serpa
authors.initials: CG
authors.lastname: Osorio-de-Castro
authors.affiliation: Núcleo de Assistência Farmacêutica, Escola Nacional de Saúde Pública Sergio Arouca, Fiocruz.
authors.forename: Rondineli Mendes
authors.initials: RM
authors.lastname: da Silva
authors.affiliation: Departamento de Economia da Saúde, Secretaria Executiva, Ministério da Saúde.
authors.forename: Aurélio de Araújo
authors.initials: Ade A
authors.lastname: Maia
authors.affiliation: Departamento de Economia da Saúde, Secretaria Executiva, Ministério da Saúde.
authors.forename: Mariana de Carvalho Barbosa
authors.initials: Mde C
authors.lastname: Ramos
authors.affiliation: Departamento de Política, Planejamento e Administração em Saúde, Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brasil, roberta_fdacosta@yahoo.com.br.
authors.forename: Rosângela
authors.initials: R
authors.lastname: Caetano
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000191:economics; D001938:Brazil; D005260:Female; D005102:Health Expenditures; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use; D011157:Population Dynamics; D015995:Prevalence; D000068836:Rivastigmine / Q000627:therapeutic use
chemical_list: D018696:Neuroprotective Agents; D000068836:Rivastigmine